Related Experiment Video

Updated: May 3, 2026

Methods to Increase the Sensitivity of High Resolution Melting Single Nucleotide Polymorphism Genotyping in Malaria
10:27

Methods to Increase the Sensitivity of High Resolution Melting Single Nucleotide Polymorphism Genotyping in Malaria

Published on: November 10, 2015

12.2K

Differential prevalence of transporter polymorphisms in symptomatic and asymptomatic falciparum malaria infections in

Stephen Tukwasibwe, Levi Mugenyi, George W Mbogo

    The Journal of Infectious Diseases
    |January 22, 2014
    PubMed

    Insights

    Wild-type Plasmodium falciparum genotypes, associated with drug resistance, were more prevalent in febrile Ugandan children than asymptomatic ones. This suggests wild-type parasites may exhibit greater virulence, impacting malaria clinical presentations.

    Area of Science:

    • Malariology
    • Genetics
    • Epidemiology

    Background:

    • Plasmodium falciparum drug resistance is a major global health concern.
    • Understanding the relationship between genetic polymorphisms and clinical outcomes is crucial for malaria control.
    • Tororo, Uganda, is an area with a high burden of malaria.

    Purpose of the Study:

    • To investigate the association between Plasmodium falciparum drug resistance-mediating polymorphisms and clinical presentations in Ugandan children.
    • To determine if specific genotypes correlate with increased parasite virulence.

    Main Methods:

    • Retrospective case-control study design.
    • Inclusion of 243 febrile children (cases) and 243 asymptomatic children (controls).
    • Multivariate analysis adjusting for age, infection complexity, and parasite density.

    Main Results:

    • Wild-type genotypes (pfcrt K76T, pfmdr1 N86Y, pfmdr1 D1246Y) were significantly more prevalent in febrile children.
    • Odds ratios for wild-type genotypes ranged from 4.08 to 4.90.
    • These findings suggest increased virulence associated with wild-type parasites.

    Conclusions:

    • Plasmodium falciparum wild-type genotypes are associated with increased risk of febrile illness in children.
    • The study indicates that certain drug resistance-mediating polymorphisms may confer a virulence advantage to the parasite.
    • Further research is needed to elucidate the mechanisms behind this observed association.

    More Related Videos

    A Multi-detection Assay for Malaria Transmitting Mosquitoes09:00

    A Multi-detection Assay for Malaria Transmitting Mosquitoes

    Published on: February 28, 2015

    12.7K
    Methods to Investigate the Regulatory Role of Small RNAs and Ribosomal Occupancy of Plasmodium falciparum10:22

    Methods to Investigate the Regulatory Role of Small RNAs and Ribosomal Occupancy of Plasmodium falciparum

    Published on: December 4, 2015

    8.2K

    Related Concept Videos

    Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

    Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

    The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
    189
    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
    159
    Principles of Pharmacogenetics: Types of Genetic Variants01:27

    Principles of Pharmacogenetics: Types of Genetic Variants

    The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
    138
    Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

    Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

    Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
    94
    Pharmacogenetics of Drug Metabolism: Overview01:27

    Pharmacogenetics of Drug Metabolism: Overview

    Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
    194